{
  "asset": "TECVAYLI (teclistamab)",
  "query_terms": [
    "TECVAYLI (teclistamab)",
    "teclistamab",
    "TECVAYLI"
  ],
  "returned_unique": 27,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT05243797",
      "title": "Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "European Myeloma Network B.V.",
      "collaborators": [
        "Janssen Pharmaceutica"
      ],
      "interventions": [
        "Teclistamab",
        "Lenalidomide"
      ],
      "last_update": "2025-12-30",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05243797"
    },
    {
      "nct_id": "NCT06285318",
      "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
      "overall_status": "RECRUITING",
      "phase": null,
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma (RRMM)"
      ],
      "lead_sponsor": "Janssen-Cilag Ltd.",
      "collaborators": [],
      "interventions": [
        "Teclistamab",
        "Talquetamab"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
    },
    {
      "nct_id": "NCT06251076",
      "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
      "overall_status": "RECRUITING",
      "phase": null,
      "conditions": [
        "Multiple Myeloma",
        "Relapsed Cancer",
        "Refractory Cancer"
      ],
      "lead_sponsor": "University Health Network, Toronto",
      "collaborators": [
        "Janssen Inc."
      ],
      "interventions": [
        "Teclistamab",
        "Tocilizumab"
      ],
      "last_update": "2025-12-10",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
    },
    {
      "nct_id": "NCT06208150",
      "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Talquetamab",
        "Pomalidomide",
        "Teclistamab",
        "Elotuzumab",
        "Dexamethasone",
        "Bortezomib"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
    },
    {
      "nct_id": "NCT07110844",
      "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Amyloid Light-chain Amyloidosis"
      ],
      "lead_sponsor": "Suzanne Lentzsch, MD",
      "collaborators": [
        "Janssen Pharmaceuticals"
      ],
      "interventions": [
        "Teclistamab",
        "Daratumumab and Hyaluronidase-fihj"
      ],
      "last_update": "2025-11-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
    },
    {
      "nct_id": "NCT04696809",
      "title": "A Phase 1/2 Study of JNJ-64007957, a Humanized BCMA * CD3 Bispecific Antibody in Japanese Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Hematologic Malignancies"
      ],
      "lead_sponsor": "Janssen Pharmaceutical K.K.",
      "collaborators": [],
      "interventions": [
        "Teclistamab"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04696809"
    },
    {
      "nct_id": "NCT04557098",
      "title": "A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Hematological Malignancies"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Teclistamab"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04557098"
    },
    {
      "nct_id": "NCT07105059",
      "title": "Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma",
      "overall_status": "RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
      "collaborators": [
        "Bristol-Myers Squibb",
        "Johnson & Johnson"
      ],
      "interventions": [
        "Teclistamab",
        "Mezigdomide"
      ],
      "last_update": "2025-11-28",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07105059"
    },
    {
      "nct_id": "NCT07030517",
      "title": "An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate Its Safety in Indian Participants With Relapsed and Refractory Multiple Myeloma Who Have Previously Received at Least 3 Prior Lines of Therapy Including an Immunomodulatory Agent, a Proteasome Inhibitor and an Anti-CD38 Antibody and Have Demonstrated Disease Progression on the Last Therapy",
      "overall_status": "RECRUITING",
      "phase": null,
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Johnson & Johnson Private Limited",
      "collaborators": [],
      "interventions": [
        "Teclistamab"
      ],
      "last_update": "2025-12-24",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07030517"
    },
    {
      "nct_id": "NCT04108195",
      "title": "A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Daratumumab",
        "Talquetamab",
        "Teclistamab",
        "Pomalidomide"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04108195"
    }
  ]
}